Alzamend Neuro Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 31, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Net Income	-7.04	-4.51	-9.95	-14.88	-12.36	-5.05
Depreciation & Amortization	0.1	0.05	0.05	0.02	0	-
Stock-Based Compensation	0.16	0.33	0.96	3.58	4.41	2.03
Other Adjustments	-	0.01	0	-	0.01	0.45
Changes in Accounts Payable	1.22	-2.29	0.05	1.71	0.69	-0.41
Changes in Other Operating Activities	0.12	-0.15	0.62	0.64	0.63	0.26
Operating Cash Flow	-5.96	-6.57	-8.27	-8.92	-6.61	-2.71
Capital Expenditures	-0.21	-0.3	-0.15	-	-0.11	-
Other Investing Activities	-	-	-	-	-	0.1
Investing Cash Flow	-0.21	-0.3	-0.15	-	-0.11	0.1
Short-Term Debt Issued	-	-	-	-	-	1.85
Net Short-Term Debt Issued (Repaid)	-	-	-	-	-	1.85
Long-Term Debt Issued	-	-	0.3	-	-	0.4
Net Long-Term Debt Issued (Repaid)	-	-	0.3	-	-	0.4
Issuance of Common Stock	0.84	2.7	1.25	0	18.91	2.2
Net Common Stock Issued (Repurchased)	0.84	2.7	1.25	0	18.91	2.2
Issuance of Preferred Stock	4.68	7.74	2.1	-	-	-
Net Preferred Stock Issued (Repurchased)	4.68	7.74	2.1	-	-	-
Other Financing Activities	-	-	-	-	-0.06	-0
Financing Cash Flow	5.52	10.44	3.65	0	18.86	4.45
Net Cash Flow	-0.64	3.57	-4.76	-8.92	12.13	1.84
Free Cash Flow	-6.17	-6.87	-8.42	-8.92	-6.72	-2.71
Free Cash Flow Per Share	-2.45	-15.24	-113.48	-123.53	-101.83	-50.40
Levered Free Cash Flow	-6.32	-7.79	-9.07	-12.51	-11.14	-2.95
Unlevered Free Cash Flow	-5.81	-7.18	-9.36	-12.5	-11.1	-5.1

SEC Filings: 10-K · 10-Q